



final

Gynecologic Cancer InterGroup (GCIG)

Cervix Cancer Committee

Friday, May 29, 2015, 10:30 a.m. – 12:30 p.m.

LaSalle I Room, Doubletree Hotel, 300 E. Ohio Street, Chicago

CHAIR: SATORU SAGAE.
CO-CHAIR: BRADLEY J. MONK

AGENDA

Please sign Attendance Forms

WELCOME & INTRODUCTIONS & COI declarations

Satoru Sagae

Approval of minutes: Nov 2014

Published:

- Hasegawa K, Nagao S, Yasuda M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for **clear cell carcinoma of the uterine corpus and cervix**. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5.
- Fujiwara H, Yokota H, Monk B, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for **cervical adenocarcinoma**. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-101.
- Satoh T, Takei Y, Treilleux I, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for **small cell carcinoma of the cervix**. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-8.
- Suneja G, Bacon M, Small W Jr, et al. **The cervix cancer research network: increasing access to cancer clinical trials in low- and middle-income countries**. Front Oncol. 2015 Feb 19;5:14.
- Chase DM, Kauderer J, Wenzel L, et al. Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204. Int J Gynecol Cancer. 2015 Feb;25(2):303-8.
- Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015 Mar;16(3):301-11.

In preparation:

- Sagae S., Monk B., Pujade-Lauraine E., Small B., Dave Gaffney D., Narayan K., and others. **Advances and Concepts in Cervical Cancer Trials A Gynecologic Cancer InterGroup (GCIG) Report.** Int J Gynecol Cancer In preparation.

Closed trials:

- EORTC 55994: Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO stage Ib2, IIa>4 cm or IIb cervical cancer Casado
- Bio-RAIDs: Biomarker evaluation in advanced stage cervical cancer by an international working group. Tumor Stages (1B2 – 4) in 7 EU countries (France, Holland, Germany, Serbia, Moldova, Romania and Belgium) S.Scholl

CURRENT ACTIVE/NEAR ACTIVATION RANDOMIZED TRIALS WITH GCIG PARTICIPATION:

- KGOG-Thai **TACO**: (RTOG, GICOM) (**CCRN** - Viet Nam, Thailand)
Randomized Clinical Trial of Weekly versus Tri-Weekly Cisplatin based
Chemoradiation in Locally Advanced Cervical Cancer S Y Ryu
- ANZGOG **OUTBACK** (GOG, RTOG) (**CCRN** - India) : Chemoradiotherapy +/-
adjuvant chemotherapy Mileschkin
- NCRI: **INTERLACE**: (**CCRN** – Romania, Belarus) INduction ChemoThERapy
in Locally Advanced CErvical Cancer. McCormack
- NCIC-CTG CX 5 **SHAPE**: (DGOG,) (**CCRN** --) A RANDOMIZED TRIAL
COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION
VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN
PATIENTS WITH LOW RISK EARLY STAGE CX CA: Plante

NRG

- KGOG-0801/GOG 263 (RTOG): RT vs CRT in intermediate risk cervix cancer
after hysterectomy SY Ryu
- GOG-0278 Conservative surgery (cone/nodes or hyst/(nodes) in early stage
cervical cancer. (evaluation of physical function and QOL) Monk
- GOG-0279 Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine
(NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT)
in Treatment of Locally Adv. Squamous Cell Carcinoma of the Vulva Monk
- RTOG-0724 (GOG): ChemoRT with and without adjuvant chemotherapy in high
risk cervix cancer after hysterectomy Small
- RTOG: A RANDOMIZED PHASE III STUDY OF STANDARD VS. IMRT PELVIC
RADIATION FOR POST-OPERATIVE TREATMENT OF ENDOMETRIAL AND
CERVICAL CANCER: TIME-C Small

EUROPE

- DGOG GROINSS-V II (EORTC, GOG) : Groningen International Study on
Sentinel Nodes in Vulvar Cancer Creutzberg for van der Zee

OTHERS:

PROPOSED OR DEVELOPING CONCEPTS (after Melbourne meeting 2014):

1. Randomized trials of hypo fractionation - D. Gaffney (RTOG)
2. A phase II trial of Neo-adjuvant chemotherapy and fertility sparing surgery for stage IB1 cervix cancer (2-4 cm) - M. Plante (NCIC)
3. International prospective validation trial of sentinel node biopsy in cervical cancer - F. Lecuru (GINECO)
4. International survey of sentinel lymph node biopsy in cervical cancer - J. Sehouli (NOGGO)
5. 1st line metastatic disease adding or versus bevacizumab - K.Tewari (GOG)
6. High risk maintenance trial -T. Herzog (GOG)

DISCUSSION

ADJOURN

Of Note: